Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions

Amalia S. Magaret; Shevin Jacob; M. Elizabeth Halloran; Katherine A. Guthrie; Craig A. Magaret; Christine Johnston; Noah R. Simon; Anna Wald

doi:10.7326/m20-2933

Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions

Amalia S. Magaret, Shevin Jacob, M. Elizabeth Halloran, Katherine A. Guthrie, Craig A. Magaret, Christine Johnston, Noah R. Simon, Anna Wald

Clinical Sciences

Research output: Contribution to journal › Comment/debate

4 Citations (Scopus)

Abstract

We propose platform trials with outcome-adaptive randomization to efficiently select the most effective coronavirus disease 2019 (COVID-19) treatments. The global spread of severe acute respiratory syndrome coronavirus 2 infection is alarming in its geographic scope and in the number of associated deaths. There are currently no treatments proven to decrease mortality from COVID-19 further than what can be achieved through supportive care. Thus far, the choice of therapeutics has been limited to existing, repurposed medications. Given that some of the medications are perceived to have low toxicity, many have been embraced without evidence. Although remdesivir was recently found to shorten time to symptom resolution, evidence for survival benefit is inconclusive

Original language	English
Pages (from-to)	576-577
Number of pages	2
Journal	Annals of Internal Medicine
Volume	173
Issue number	7
Early online date	11 Jun 2020
DOIs	https://doi.org/10.7326/m20-2933
Publication status	Published - 6 Oct 2020

Access to Document

10.7326/m20-2933

Magaret Coronavirus 2020June05 cleanAccepted author manuscript, 37.8 KB

Cite this

@article{dae65d824abc48deb9ea2ed8c9240890,

title = "Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions",

abstract = "We propose platform trials with outcome-adaptive randomization to efficiently select the most effective coronavirus disease 2019 (COVID-19) treatments. The global spread of severe acute respiratory syndrome coronavirus 2 infection is alarming in its geographic scope and in the number of associated deaths. There are currently no treatments proven to decrease mortality from COVID-19 further than what can be achieved through supportive care. Thus far, the choice of therapeutics has been limited to existing, repurposed medications. Given that some of the medications are perceived to have low toxicity, many have been embraced without evidence. Although remdesivir was recently found to shorten time to symptom resolution, evidence for survival benefit is inconclusive",

author = "Magaret, \{Amalia S.\} and Shevin Jacob and Halloran, \{M. Elizabeth\} and Guthrie, \{Katherine A.\} and Magaret, \{Craig A.\} and Christine Johnston and Simon, \{Noah R.\} and Anna Wald",

year = "2020",

month = oct,

day = "6",

doi = "10.7326/m20-2933",

language = "English",

volume = "173",

pages = "576--577",

journal = "Annals of Internal Medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "7",

}

TY - JOUR

T1 - Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions

AU - Magaret, Amalia S.

AU - Jacob, Shevin

AU - Halloran, M. Elizabeth

AU - Guthrie, Katherine A.

AU - Magaret, Craig A.

AU - Johnston, Christine

AU - Simon, Noah R.

AU - Wald, Anna

PY - 2020/10/6

Y1 - 2020/10/6

N2 - We propose platform trials with outcome-adaptive randomization to efficiently select the most effective coronavirus disease 2019 (COVID-19) treatments. The global spread of severe acute respiratory syndrome coronavirus 2 infection is alarming in its geographic scope and in the number of associated deaths. There are currently no treatments proven to decrease mortality from COVID-19 further than what can be achieved through supportive care. Thus far, the choice of therapeutics has been limited to existing, repurposed medications. Given that some of the medications are perceived to have low toxicity, many have been embraced without evidence. Although remdesivir was recently found to shorten time to symptom resolution, evidence for survival benefit is inconclusive

AB - We propose platform trials with outcome-adaptive randomization to efficiently select the most effective coronavirus disease 2019 (COVID-19) treatments. The global spread of severe acute respiratory syndrome coronavirus 2 infection is alarming in its geographic scope and in the number of associated deaths. There are currently no treatments proven to decrease mortality from COVID-19 further than what can be achieved through supportive care. Thus far, the choice of therapeutics has been limited to existing, repurposed medications. Given that some of the medications are perceived to have low toxicity, many have been embraced without evidence. Although remdesivir was recently found to shorten time to symptom resolution, evidence for survival benefit is inconclusive

U2 - 10.7326/m20-2933

DO - 10.7326/m20-2933

M3 - Comment/debate

SN - 0003-4819

VL - 173

SP - 576

EP - 577

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

IS - 7

ER -

Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions

Abstract

Access to Document

Fingerprint

Cite this